• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment.

作者信息

Busato Wilson F S

机构信息

Disciplina de Urologia, Universidade do Vale do Itajaí - Univali, Itajaí, SC, Brasil.

Departamento de Uro-Oncologia, Sociedade Brasileira de Urologia - SBU, Rio de Janeiro, RJ, Brasil.

出版信息

Int Braz J Urol. 2020 May-Jun;46(3):456-458. doi: 10.1590/S1677-5538.IBJU.2020.03.02.

DOI:10.1590/S1677-5538.IBJU.2020.03.02
PMID:32167713
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7088470/
Abstract
摘要

相似文献

1
Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment.5α-还原酶抑制剂的使用与前列腺癌诊断和治疗的延迟
Int Braz J Urol. 2020 May-Jun;46(3):456-458. doi: 10.1590/S1677-5538.IBJU.2020.03.02.
2
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.甾体 5α-还原酶和 17α-羟化酶/17,20-裂合酶（CYP17）抑制剂，可用于治疗前列腺疾病。
J Steroid Biochem Mol Biol. 2013 Sep;137:199-222. doi: 10.1016/j.jsbmb.2013.04.006. Epub 2013 May 18.
3
Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.5α-还原酶抑制剂对具有有利特征的局限性前列腺癌主动监测男性疾病分类的影响。
J Urol. 2018 Feb;199(2):445-452. doi: 10.1016/j.juro.2017.08.006. Epub 2017 Aug 5.
4
Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.5α-还原酶抑制剂在前列腺癌防治中的作用。
Urology. 2012 Jun;79(6):1197-205. doi: 10.1016/j.urology.2012.01.024. Epub 2012 Mar 23.
5
Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.5α-还原酶抑制剂使用对前列腺癌筛查的影响。
J Urol. 2017 Aug;198(2):305-309. doi: 10.1016/j.juro.2017.02.069. Epub 2017 Feb 16.
6
Prostate cancer: alcohol, cancer and 5α-reductase inhibitors-is there a link?前列腺癌：酒精、癌症与 5α-还原酶抑制剂——它们之间是否存在关联？
Nat Rev Urol. 2014 May;11(5):253-4. doi: 10.1038/nrurol.2014.90. Epub 2014 Apr 29.
7
Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.关于：非那雄胺对有前列腺癌风险男性血清雄烯二酮、睾酮及其5α-还原代谢产物水平的影响
J Steroid Biochem Mol Biol. 2013 Nov;138:462. doi: 10.1016/j.jsbmb.2013.06.013. Epub 2013 Jul 9.
8
Revisiting 5α-reductase inhibitors and the risk of prostate cancer.重新审视 5α-还原酶抑制剂与前列腺癌风险。
Nat Rev Urol. 2018 Jul;15(7):400-401. doi: 10.1038/s41585-018-0018-9.
9
Prostate cancer chemoprevention with 5α-reductase inhibitors.5α-还原酶抑制剂用于前列腺癌化学预防
Urol Oncol. 2012 Sep;30(5):553-4. doi: 10.1016/j.urolonc.2011.02.006.
10
Finasteride, a selective 5-alpha-reductase inhibitor, in the prevention and treatment of human prostate cancer.非那雄胺，一种选择性5α-还原酶抑制剂，用于预防和治疗人类前列腺癌。
Clin Prostate Cancer. 2004 Mar;2(4):206-8. doi: 10.1016/s1540-0352(11)70045-2.

引用本文的文献

1
Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil.对接受5-α还原酶抑制剂治疗的良性前列腺增生男性患者的前列腺特异性抗原监测：西班牙和巴西泌尿外科医生真实临床实践的非干预性横断面研究
BMC Urol. 2025 Jan 31;25(1):22. doi: 10.1186/s12894-025-01701-1.
2
Rates of False-Negative Screening in Prostate Specific Antigen Secondary to 5-Alpha Reductase Inhibitor Usage: A Quality-Improvement Initiative.基于 5α-还原酶抑制剂使用的前列腺特异性抗原检测中假阴性率：一项质量改进计划。
Int Braz J Urol. 2022 Jul-Aug;48(4):688-695. doi: 10.1590/S1677-5538.IBJU.2022.0099.

本文引用的文献

1
Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.良性前列腺增生症管理的流行病学与治疗方式
Transl Androl Urol. 2019 Oct;8(5):529-539. doi: 10.21037/tau.2019.10.01.
2
Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.5α-还原酶抑制剂治疗与前列腺癌诊断和死亡时间的关系。
JAMA Intern Med. 2019 Jun 1;179(6):812-819. doi: 10.1001/jamainternmed.2019.0280.
3
Long-Term Effects of Finasteride on Prostate Cancer Mortality.非那雄胺对前列腺癌死亡率的长期影响。
N Engl J Med. 2019 Jan 24;380(4):393-394. doi: 10.1056/NEJMc1809961.
4
Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies.5α还原酶抑制剂预防前列腺癌：概念与争议
Curr Opin Urol. 2018 Jan;28(1):42-45. doi: 10.1097/MOU.0000000000000464.
5
Medical treatment of benign prostatic hyperplasia.良性前列腺增生的医学治疗。
Rev Urol. 2011;13(1):20-33.
6
The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?5α-还原酶抑制剂在前列腺病理生理学中的作用：抑制1型同工酶是否具有额外优势？
Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. doi: 10.5489/cuaj.1114.
7
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.5α-还原酶抑制剂在良性前列腺增生和降低前列腺癌风险中的应用
Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402. doi: 10.1016/j.beem.2008.01.016.
8
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.非那雄胺治疗患者前列腺癌的预测：来自前列腺癌预防试验的结果。
J Clin Oncol. 2007 Jul 20;25(21):3076-81. doi: 10.1200/JCO.2006.07.6836.
9
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.非那雄胺对前列腺特异性抗原水平的长期影响：前列腺癌预防试验的结果
J Urol. 2005 Sep;174(3):877-81. doi: 10.1097/01.ju.0000169255.64518.fb.